Skip to main content

Table 4 Most common adverse events by CTCAE grade (incidence of all grades: ≥ 15%)

From: Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Adverse events Severity, n (%)
All grades Grade 1 Grade 2 Grade 3
Hematologic
PB regimen (n = 51)
 Anemia 30 (58.8) 18 (35.3) 9 (17.6) 3 (5.9)
 Leukopenia 21 (41.2) 10 (19.6) 8 (15.7) 3 (5.9)
 Neutropenia 19 (37.3) 2 (3.9) 9 (17.6) 8 (15.7)
Eribulin maintenance therapy (n = 45)
 Anemia 26 (57.8) 21 (46.7) 4 (8.9) 1 (2.2)
 Leukopenia 24 (53.3) 9 (20.0) 10 (22.2) 5 (11.1)
 Neutropenia 23 (51.1) 2 (4.4) 12 (26.7) 9 (20.0)
Nonhematologic
PB regimen (n = 51)
 Alopecia 51 (100.0) 2 (3.9) 49 (96.1) –
 Peripheral sensory neuropathy 37 (72.5) 28 (54.9) 8 (15.7) 1 (2.0)
 Increased AST 15 (29.4) 13 (25.5) 1 (2.0) 1 (2.0)
 Dysgeusia 15 (29.4) 15 (29.4) 0 (0.0) –
 Epistaxis 15 (29.4) 15 (29.4) 0 (0.0) 0 (0.0)
 Fatigue 12 (23.5) 10 (19.6) 2 (3.9) 0 (0.0)
 Arthralgia 12 (23.5) 12 (23.5) 0 (0.0) 0 (0.0)
 Rash 12 (23.5) 12 (23.5) 0 (0.0) 0 (0.0)
 Increased ALT 10 (19.6) 8 (15.7) 2 (3.9) 0 (0.0)
 Anorexia 10 (19.6) 7 (13.7) 3 (5.9) 0 (0.0)
 Nail discoloration 10 (19.6) 10 (19.6) – –
 Peripheral motor neuropathy 9 (17.6) 8 (15.7) 0 (0.0) 0 (0.0)
 Myalgia 8 (15.7) 8 (15.7) 0 (0.0) 0 (0.0)
Eribulin maintenance therapy (n = 45)
 Peripheral sensory neuropathy 37 (82.2) 18 (40.0) 17 (37.8) 2 (4.4)
 Increased AST 25 (55.6) 21 (46.7) 3 (6.7) 1 (2.2)
 Dysgeusia 16 (35.6) 13 (28.9) 3 (6.7) –
 Increased ALT 16 (35.6) 14 (31.1) 2 (4.4) 0 (0.0)
 Alopecia 15 (33.3) 8 (17.8) 7 (15.6) –
 Fatigue 14 (31.1) 10 (22.2) 4 (8.9) 0 (0.0)
 Anorexia 14 (31.1) 11 (24.4) 3 (6.7) 0 (0.0)
 Peripheral motor neuropathy 13 (28.9) 10 (22.2) 3 (6.7) 0 (0.0)
 Increased creatinine 13 (28.9) 12 (26.7) 1 (2.2) 0 (0.0)
 Nausea 11 (24.4) 11 (24.4) 0 (0.0) 0 (0.0)
 Arthralgia 10 (22.2) 9 (20.0) 1 (2.2) 0 (0.0)
 Myalgia 9 (20.0) 7 (15.6) 2 (4.4) 0 (0.0)
 Nail loss 9 (20.0) 4 (8.9) 5 (11.1) –
 Constipation 8 (17.8) 5 (11.1) 3 (6.7) 0 (0.0)
 Epistaxis 7 (15.6) 7 (15.6) 0 (0.0) 0 (0.0)
 Nail discoloration 7 (15.6) 7 (15.6) – –
  1. CTCAE common terminology criteria for adverse events, PB paclitaxel + bevacizumab, AST aspartate transaminase, ALT alanine transaminase; −, no definition
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us